The New York-based investment firm, Altium Capital Management, LP has recently announced impressive numbers as part of their growth report, number which are reflecting the activities of last year. Altium is the newest venture of Jacob Gottlieb and Mark Gottlieb, who are key players in the firm, working as Chief Investment Officer and Managing Partner, and Chief Operating Officer respectively.
Prior to launching Altium, Jacob Gottlieb worked for Visium Asset Management, a hedge fund that he founded back in 2005, peaking in 2016 with 200 employees in offices in London, San Francisco and New York City managing $8 billion. Before establishing Visium, he was a founding member of Balyasny Asset Management, becoming a top earner and having a reputation for his big portfolio gains. In addition, he worked at Merlin before taking on his role at Balyasny Asset Management, and gained success as an investment portfolio manager. Gottlieb holds a BA degree in Economics, earned from Brown University, and also has an MD received from New York University Medical School.
The other key player at Altium, Mark Gottlieb also worked at Visium prior to being a part of the new venture, and was Partner as well as Chief Administrative Officer. He was also part of the team at Balyasny Asset Management, and focused on negotiating private investments in publicly traded companies in development stage healthcare. Mark Gottlieb has a BA degree in Economics from Vassar College, and an MBA degree in Entrepreneurship & Venture Capital received from Cornell University.
Altium Growth Fund, a product of Altium Capital, reported returns of 7.73%, based on its performance from June of 2018 to October, for a total of 5 months. Being a healthcare-oriented investment firm, Altium focuses on investment opportunities which are related to growth companies within the healthcare industry. Jacob Gottlieb seeks out companies which are offering meaningful advances when it comes to health and medical treatment. The Delaware-based Altium Growth Fund focuses mainly on mid-cap equities, small-cap equities, as well as equity-linked products, investing in US as well as international healthcare sub-sectors like medical devices, medical technology, life science tools, services, major and specialty pharma, and biotech.
Altium Capital Management is focusing on generating returns in various equity-focused products in the healthcare sector. The firm puts an emphasis on fundamental research, having a focus on generating positive expected-value trades via the analysis of asymmetric risk-reward opportunities. The firm was launched in 2017, and besides Jacob and Mark Gottlieb, Altium also has team of experienced professionals who achieved success in various areas.
Altium Capital made investment recently in companies within the healthcare sector, including a 5.61% stake in Oramed Pharmaceuticals, as well as investments in Amarin Corporation, and Oragenics. Oramed focuses on designing an oral treatment alternative for patients with diabetes who are currently receiving injectable drugs. Amarin Corporation’s work is around the development of drugs that improve cardiovascular health, and Oragenics puts an emphasis on novel antibiotics designed to fight infectious diseases, as well as on the development of effective treatment for oral mucositis through replacement therapy.
The firm approaches investment based on a strong research process which focuses on capitalizing on pricing inefficiencies in the mid-cap and small-cap sectors. Altium’s investment process is based on bottom-up analysis for each security selection, being designed to generate returns on long as well as short positions which are combined with exposure hedging. The objective is to create risk-adjusted returns using low correlation to equity investments. The investment process includes idea generation, which is followed by stock selection and the construction of the portfolio, culminating with trade execution as well as an exit strategy.
This is a supported post